Half-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization-Reference-Cited by-同舟云学术

Half-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization

Published:2019-07-16 Issue:8 Volume:16 Page:3665-3677
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Bech Esben M.¹²,Kaiser Anette³,Bellmann-Sickert Kathrin³,Nielsen Søren S.-R.²,Sørensen Kasper K.²,Elster Lisbeth¹,Hatzakis Nikos²⁴,Pedersen Søren L.¹,Beck-Sickinger Annette G.³^ORCID,Jensen Knud J.²^ORCID

Affiliation:

1. Gubra Aps, Hørsholm, Denmark

2. Department of Chemistry, University of Copenhagen, Frederiksberg, Denmark

3. Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Leipzig, Germany

4. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.9b00554

Reference69 articles.

1. Gut hormone PYY3-36 physiologically inhibits food intake

2. Inhibition of Food Intake in Obese Subjects by Peptide YY3–36

3. Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development

4. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis

5. The Role of Gut Hormone Peptide YY in Energy and Glucose Homeostasis: Twelve Years On

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. G protein–coupled receptor endocytosis generates spatiotemporal bias in β-arrestin signaling;Science Signaling;2024-06-25

2. Methods for Engineering Binders to Multi-Pass Membrane Proteins;Bioengineering;2023-11-24

3. Evolution of peptide YY analogs for the management of type 2 diabetes and obesity;Bioorganic Chemistry;2023-11

4. Receptor endocytosis orchestrates the spatiotemporal bias of β-arrestin signaling;2023-04-28

5. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist;European Journal of Medicinal Chemistry;2023-02